MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma.

Key facts

Study ID

NCT00059995

Run by

Memorial Sloan Kettering Cancer Center

Starts

2003-01-01

Expected to finish

2009-11-01

Last updated by the study team

2013-05-30

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.